Key Takeaways
- • FreeMind Investments (FMI), a venture capital fund co-launched by FreeMind Group and Daewoong Pharmaceutical, has invested in General Proximity, a San Francisco-based biotech company specializing in induced proximity medicines.
- • General Proximity has raised over $20 million to date and operates a proprietary "effectome" discovery engine designed to identify effector proteins that modulate disease-causing proteins, targeting previously intractable therapeutic areas.
- • The company has secured five "Golden Ticket" awards from major pharmaceutical companies (AbbVie, Servier, Astellas, Ono, Bristol-Myers Squibb), validating its technology platform and commercial traction.
- • General Proximity recently announced a strategic multi-target collaboration with Daiichi Sankyo using its OmniTAC platform for oncology programs, alongside non-dilutive funding from ARPA-H and the NIH's National Cancer Institute.
- • The investment reflects confidence in General Proximity's proximity therapeutic approach and signals potential future strategic collaboration opportunities with Daewoong Pharmaceutical across oncology, cardiometabolic disease, neurodegeneration, and longevity programs.
Summary
FreeMind Investments, a venture capital fund established through a partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., has completed an investment in General Proximity, a San Francisco-based biotechnology company advancing next-generation induced proximity medicines. The investment underscores strong institutional validation of General Proximity's scientific platform and indicates Daewoong's interest in potential future strategic collaboration with the company.
General Proximity has developed a mechanism-agnostic proximity discovery engine centered on scanning the "effectome"—the comprehensive set of effector proteins capable of modulating disease-causing proteins to control disease biology. This proprietary approach enables the development of proximity therapeutics targeting previously intractable disease targets. The company has accumulated over $20 million in total funding and is advancing programs across multiple therapeutic areas, including oncology, cardiometabolic disease, neurodegeneration, and longevity.
The company has achieved significant commercial validation through five "Golden Ticket" awards from major pharmaceutical companies including AbbVie, Servier, Astellas, Ono, and Bristol-Myers Squibb, signaling strong industry interest in its technology platform. General Proximity has also secured non-dilutive funding support from ARPA-H and the NIH's National Cancer Institute. Most recently, the company announced a strategic multi-target collaboration with Daiichi Sankyo to apply its proprietary OmniTAC platform to oncology development programs.
FreeMind Group, founded in 1999, operates as a leading non-dilutive funding consultancy for life science organizations, having secured over $2 billion in aggregate funding for its clients to date and generating over $100 million in annual revenue. The firm's investment in General Proximity through its partnership vehicle with Daewoong reflects both confidence in the company's technological differentiation and the strategic priorities of a major pharmaceutical partner seeking access to next-generation therapeutic modalities.
General Proximity has developed a mechanism-agnostic proximity discovery engine centered on scanning the "effectome"—the comprehensive set of effector proteins capable of modulating disease-causing proteins to control disease biology. This proprietary approach enables the development of proximity therapeutics targeting previously intractable disease targets. The company has accumulated over $20 million in total funding and is advancing programs across multiple therapeutic areas, including oncology, cardiometabolic disease, neurodegeneration, and longevity.
The company has achieved significant commercial validation through five "Golden Ticket" awards from major pharmaceutical companies including AbbVie, Servier, Astellas, Ono, and Bristol-Myers Squibb, signaling strong industry interest in its technology platform. General Proximity has also secured non-dilutive funding support from ARPA-H and the NIH's National Cancer Institute. Most recently, the company announced a strategic multi-target collaboration with Daiichi Sankyo to apply its proprietary OmniTAC platform to oncology development programs.
FreeMind Group, founded in 1999, operates as a leading non-dilutive funding consultancy for life science organizations, having secured over $2 billion in aggregate funding for its clients to date and generating over $100 million in annual revenue. The firm's investment in General Proximity through its partnership vehicle with Daewoong reflects both confidence in the company's technological differentiation and the strategic priorities of a major pharmaceutical partner seeking access to next-generation therapeutic modalities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.